Several ongoing clinical trials in patients with ovarian cancer, with pancreatic cancer or with mesothelioma suggest that MSLN-specific T-cell responses have a beneficial effect [16]–[22]. The gene discussed is MSLN; the disease is familial pancreatic carcinoma.